Not sure if its a retread
Citation: The PLOS ONE Staff (2014) Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. PLoS ONE 9(8): e106797. doi:10.1371/journal.pone.0106797
This correction simply updates the participant and funding disclosures.
Here's the straight skinny from PlosOne:
There are some missing funding sources for this article. Please refer to the correct funding statement below:
"The studies in this manuscript were funded by Exelixis Inc.; PO1 National Institutes of Health grant (PO1CA085859); Pacific Northwest Prostate Cancer SPORE grant (P50CA097186); Prostate Cancer Foundation; Richard M. Lucas Foundation; and University of Washington Bridge funding. Two of the co-authors (DTA and FS) are employees of Exelixis. They were involved in study design, data analyses, decision to publish and preparation of the manuscript"